GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (NAS:OCS) » Definitions » Short-Term Debt

Oculis Holding AG (Oculis Holding AG) Short-Term Debt : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Short-Term Debt?

Oculis Holding AG's Short-Term Debt for the quarter that ended in Mar. 2024 was $0.00 Mil.

Oculis Holding AG Short-Term Debt Historical Data

The historical data trend for Oculis Holding AG's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Short-Term Debt Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Short-Term Debt
- - - -

Oculis Holding AG Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Oculis Holding AG Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Oculis Holding AG Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Oculis Holding AG (Oculis Holding AG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (NAS:OCS) » Definitions » Short-Term Debt
Comparable Companies
LXRX MGNX ICVX SPRY CHRS TERN AURA ERAS NAUT MLYS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CR5:Germany
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Website
https://www.oculis.com
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.